Your browser doesn't support javascript.
loading
Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse.
Su, Heng-Chuan; Zhu, Yao; Ling, Guo-Wen; Hu, Si-Long; Xu, Xiao-Ping; Dai, Bo; Ye, Ding-Wei.
Afiliación
  • Su HC; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Zhu Y; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Ling GW; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Hu SL; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Xu XP; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Dai B; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Ye DW; Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
Asian J Androl ; 19(3): 267-271, 2017.
Article en En | MEDLINE | ID: mdl-27976632
Using conventional imaging modalities, it is difficult to detect recurrent lesions in prostate cancer patients who have undergone biochemical relapse, especially in patients with low prostate-specific antigen (PSA) levels. We retrospectively reviewed the files of fifty patients with histopathologically confirmed prostate cancer who underwent 99mTc-labeled prostate-specific membrane antigen (PSMA) single-photon emission computed tomography (SPECT)/computed tomography (CT), magnetic resonance imaging (MRI), and bone scan within a 30-day period. PSMA-SPECT/CT indicated metastatic lesions in 39 patients and had a higher detection rate (78.0%) than bone scan (34.0%) or MRI (40.0%). The diagnostic efficiency of PSMA-SPECT/CT imaging for bone and lymph node metastases (50.0% and 42.0%) was better than bone scan (34.0% and 0.0%) or MRI (24.0% and 20.0%). PSMA-SPECT/CT provided a higher detection rate at serum PSA levels of ≤1 ng ml-1, 1-4 ng ml-1, 4-10 ng ml-1, and >10 ng ml-1. No correlation was found between Gleason score, PSA level, and the tracer tumor/background ratio of metastatic lesions. With the aid of PSMA-SPECT/CT imaging, the therapeutic strategy was changed for 31 patients, and this may have enhanced their clinical outcome. In conclusion, PSMA-SPECT/CT imaging could detect more metastatic lesions and achieve a higher detection rate than conventional imaging modalities at different serum PSA levels in prostate cancer patients who had undergone biochemical relapse.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Radiofármacos / Glutamato Carboxipeptidasa II / Antígenos de Superficie Tipo de estudio: Observational_studies Límite: Humans / Male Idioma: En Revista: Asian J Androl Asunto de la revista: MEDICINA REPRODUTIVA / UROLOGIA Año: 2017 Tipo del documento: Article País de afiliación: China Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Radiofármacos / Glutamato Carboxipeptidasa II / Antígenos de Superficie Tipo de estudio: Observational_studies Límite: Humans / Male Idioma: En Revista: Asian J Androl Asunto de la revista: MEDICINA REPRODUTIVA / UROLOGIA Año: 2017 Tipo del documento: Article País de afiliación: China Pais de publicación: China